Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.60−0.35 (-2.70%)

Close on Nov 13, 2026Market cap $884.12MP/E 315.0Yield –

Pharming price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Pharming's price to sales ratio was 2.5× on Nov 11, 2026, against 4.0× a year earlier. Over the last 5 years it ranged from 1.9× to 4.7×, with a median of 2.9×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.5×	−1.5
2025	Dec 31, 2025	4.0×	+1.3
2024	Dec 31, 2024	2.8×	−0.9
2023	Dec 29, 2023	3.6×	+0.1
2022	Dec 30, 2022	3.6×	+0.9
2021	Dec 31, 2021	2.7×	−2.4
2020	Dec 31, 2020	5.1×	–